Literature DB >> 15966968

Hyperbaric oxygen as an adjunctive treatment for zygomycosis.

B V John, G Chamilos, D P Kontoyiannis.   

Abstract

Zygomycosis is a rare but emerging mycosis. Because of the sub-optimal efficacy of the standard antifungal treatment for this disease, hyperbaric oxygen (HBO) has been used occasionally as an adjunctive therapeutic modality. A review of 28 published cases of zygomycosis indicates that adjunctive HBO may be beneficial in diabetic patients (94% survival), whereas its benefit in the small group of patients with haematological malignancies or bone marrow transplants is doubtful (33% survival; p 0.02). Prolonged courses of HBO were associated with a higher survival (100% survival; p 0.003). Additional studies are required to assess the optimal timing and dose for HBO treatment.

Entities:  

Mesh:

Year:  2005        PMID: 15966968     DOI: 10.1111/j.1469-0691.2005.01170.x

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN: 1198-743X            Impact factor:   8.067


  42 in total

1.  Posaconazole as salvage therapy for zygomycosis.

Authors:  R N Greenberg; K Mullane; J-A H van Burik; I Raad; M J Abzug; G Anstead; R Herbrecht; A Langston; K A Marr; G Schiller; M Schuster; J R Wingard; C E Gonzalez; S G Revankar; G Corcoran; R J Kryscio; R Hare
Journal:  Antimicrob Agents Chemother       Date:  2006-01       Impact factor: 5.191

2.  Treatment options in emerging mold infections.

Authors:  Patricia Muñoz; Jesús Guinea; Emilio Bouza
Journal:  Curr Infect Dis Rep       Date:  2008-11       Impact factor: 3.725

3.  Susceptibility profiles of amphotericin B and posaconazole against clinically relevant mucorales species under hypoxic conditions.

Authors:  Elisabeth Maurer; Ulrike Binder; Manuela Sparber; Michaela Lackner; Rita Caramalho; Cornelia Lass-Flörl
Journal:  Antimicrob Agents Chemother       Date:  2014-12-01       Impact factor: 5.191

Review 4.  Hypoxia and fungal pathogenesis: to air or not to air?

Authors:  Nora Grahl; Kelly M Shepardson; Dawoon Chung; Robert A Cramer
Journal:  Eukaryot Cell       Date:  2012-03-23

Review 5.  Mucormycosis caused by unusual mucormycetes, non-Rhizopus, -Mucor, and -Lichtheimia species.

Authors:  Marisa Z R Gomes; Russell E Lewis; Dimitrios P Kontoyiannis
Journal:  Clin Microbiol Rev       Date:  2011-04       Impact factor: 26.132

6.  Emergence of opportunistic mould infections in the hematopoietic stem cell transplant patient.

Authors:  Arlo Upton; Kieren A Marr
Journal:  Curr Infect Dis Rep       Date:  2006-11       Impact factor: 3.725

7.  Zygomycosis: an emerging fungal infection with new options for management.

Authors:  Carol A Kauffman; Anurag N Malani
Journal:  Curr Infect Dis Rep       Date:  2007-11       Impact factor: 3.725

8.  Mind the gap: Management of an emergent and threatening invasive fungal infection-a case report of rhino-orbital-cerebral and pulmonary mucormycosis.

Authors:  Joana Cortez; Bruno Costa Gomes; Andrea Speidel; Conceição Peixoto; Elina Selicka; Cristina Valente; Paulo Figueiredo; António Vieira
Journal:  Med Mycol Case Rep       Date:  2013-03-14

9.  Recent advances in the treatment of mucormycosis.

Authors:  Brad Spellberg; Ashraf S Ibrahim
Journal:  Curr Infect Dis Rep       Date:  2010-11       Impact factor: 3.725

10.  Invasive mold infections following combat-related injuries.

Authors:  Tyler Warkentien; Carlos Rodriguez; Bradley Lloyd; Justin Wells; Amy Weintrob; James R Dunne; Anuradha Ganesan; Ping Li; William Bradley; Lakisha J Gaskins; Françoise Seillier-Moiseiwitsch; Clinton K Murray; Eugene V Millar; Bryan Keenan; Kristopher Paolino; Mark Fleming; Duane R Hospenthal; Glenn W Wortmann; Michael L Landrum; Mark G Kortepeter; David R Tribble
Journal:  Clin Infect Dis       Date:  2012-10-05       Impact factor: 9.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.